Fei Luo
Chairman, Managing Director and General Manager @ Green Pine Capital Partners
Shenzhen, China
Fei Luo is a Series A investor at Green Pine Capital Partners in Shenzhen focused on Biotechnology and Medical. Luo Fei is the chairman, managing director, and general manager of GPCP. He is also the general manager of IER Venture Capital, the standing director of Technology Enterprise Association of China, the deputy general secretary of Venture Capital Industry Association of Shenzhen, and the vice president of Management Consulting Association ofShenzhen.Mr. Luo was the deputy general manager of Shenzhen AnXin Financial Consulting Company, in charge of developing the first securities database in China, organized first online IPO in China. He was the general manager of Shenzhen BeiDaZongHeng Financial Consulting Company, and served as financial consultant of several noted enterprises, including BeiDa Founder Group, Shenzhen KeXing Biology Group, Hangzhou HuaLi Group, etc.Served on boards and supervisory boards of several companies, including Coship Electronics, etc., Mr. Luo has abundant experiences in investment management and IPO.Mr. Luo obtained his BS in Economics and MS in International Economics from Peking University.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Fei Luo invests in
Stages Fei Luo invests in
Countries Fei Luo invests in
Investment Focus
Industry
- Biotechnology 5 (63%)
- Medical 2 (25%)
- Biopharma 2 (25%)
- Energy 1 (13%)
- Health Care 1 (13%)
Stage
- Series A 4 (50%)
- Seed 2 (25%)
- Angel 1 (13%)
- Series B 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Signet Therapeutics
|
Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models. | $11.5M / Series A / Jan 14, 2026 | |
YolTech Therapeutics
|
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M / Series B / Sep 11, 2025 | |
Neurogin
|
Neurogin is a bioelectronics company that provides reliable monitoring and auxiliary diagnostic tools for clinical and health institutions and focuses on advanced engineering methods for brain science research and clinical diagnosis. | Seed / Aug 23, 2024 | |
Guorui Xiechuang
|
Guorui Xiechuang is a joint venture subsidiary of Betterray New Materials Group Co., Ltd., provides power + energy storage products and system integration solutions for global customers. | $14.1M / Seed / May 25, 2023 | |
|
Signet Therapeutics
|
Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models. | Angel / Feb 16, 2022 | |
|
Analytical Biosciences
|
Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of humandiseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies. | Series A / May 26, 2021 | |
Sungen Biomedical
|
Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics. | $41.7M / Series A | |
Enrikenuo
|
Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs. | $28.1M / Series A |
Co-Investors
About Green Pine Capital Partners
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Green Pine Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ciqiong Chen
Managing Director and CFO
|
|||
|
Fei Luo
Chairman, Managing Director and General Manager
|
|||
Aaron Zhang
Partner
|
|||
Chengcheng Guo
Executive Partner of Changfeng Fund and Investment Director
|
|||
|
Liu Hao
Founder & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Fei Luo invest in?
Fei Luo invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Fei Luo last invest?
The most recent investment recorded for Fei Luo closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
